Skip to main content

Table 3 Hazard ratiosa according to tertiles of serum 25(OH)D and time between diagnosis and blood collection

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

 

Serum 25(OH)D

 

Continuous

Categorized

 

per 10 nmol/L decrement

< 35 nmol/L

35-55 nmol/L

≥ 55 nmol/L

Outcome

No.

(events)

HR

95% CI

P trend b

No.

(events)

HR

95% CI

No.

(events)

HR

95% CI

No.

(events)

HR

95% CI

Overall mortality

             

   All

1,265 (174)

1.08

1.00 to 1.17

0.07

422 (82)

1.55

1.00 to 2.39

397 (44)

0.72

0.45 to 1.17

446 (48)

1.00

-

   < 2 years

1,249 (172)

1.09

1.00 to 1.17

0.05

418 (82)

1.57

1.01 to 2.43

394 (44)

0.75

0.46 to 1.22

437 (46)

1.00

-

   < 1 year

1,093 (151)

1.13

1.03 to 1.22

0.02

375 (77)

1.81

1.11 to 2.94

353 (39)

0.82

0.48 to 1.42

365 (35)

1.00

-

   < 0.5 year

807 (119)

1.15

1.03 to 1.26

0.02

277 (63)

2.19

1.21 to 3.97

275 (33)

0.96

0.50 to 1.83

255 (23)

1.00

-

Distant disease

             

   All

1,074 (135)

1.14

1.05 to 1.24

0.006

338 (63)

2.09

1.29 to 3.41

342 (37)

1.16

0.70 to 1.94

394 (35)

1.00

-

   < 2 years

1,059 (133)

1.15

1.05 to 1.25

0.005

335 (63)

2.11

1.30 to 3.45

339 (37)

1.17

0.70 to 1.95

385 (33)

1.00

-

   < 1 year

925 (119)

1.15

1.05 to 1.26

0.007

298 (59)

2.24

1.32 to 3.79

302 (32)

1.28

0.74 to 2.22

325 (28)

1.00

-

   < 0.5 year

685 (95)

1.13

1.01 to 1.25

0.05

219 (48)

2.16

1.18 to 3.98

235 (25)

1.12

0.60 to 2.10

231 (22)

1.00

-

  1. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; HR, hazard ratio.
  2. a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection.
  3. b Calculated by using serum 25(OH)D as a continuous variable.